Tumorigenesis facilitated by Pten deficiency in the skin: Evidence of p53-Pten complex formation on the initiation phase

Cancer Science

Volumn 95, Issue 8, 2004, Pages 639-643

  Komazawa, Nobuyasu ^a   Suzuki, Akira ^b   Sano, Shigetoshi ^a   Horie, Kyoji ^a,c   Matsuura, Nariaki ^c   Mak, Tak Wah ^d   Nakano, Toru ^e   Takeda, Junji ^a,c   Kondoh, Gen ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY   (Japan)

^d UNIVERSITY OF TORONTO   (Canada)

^e OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 O METHYLPHORBOL 13 ACETATE 12 MYRISTATE; DIMETHYLBENZ[A]ANTHRACENE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P21; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ISOLATION; CLINICAL OBSERVATION; CLINICAL PROTOCOL; COMPLEX FORMATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; EXPOSURE; FEMALE; KERATINOCYTE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN TARGETING; SKIN CARCINOGENESIS; SKIN PAPILLOMA; UPREGULATION; WILD TYPE;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, TOPICAL; ANIMALS; APOPTOSIS; CARCINOGENS; DNA DAMAGE; GENES, TUMOR SUPPRESSOR; GERM-LINE MUTATION; KERATINOCYTES; MICE; MICE, KNOCKOUT; PAPILLOMA; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; SKIN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 4544239426     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03322.x     Document Type: Article

References (25)

1. Li J, Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.
2. Marsh DJ, Dahia PL, Zheng Z et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16: 333-4.
3. Liaw D, Marsh DJ, Li J et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet, 1997; 16: 64-7.
4. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273: 13375-8.
5. Stambolic V, Suzuki A, de la Pompa JL et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
6. Kiguchi K, Beltran L, Rupp T et al. Altered expression of epidermal growth factor receptor ligands in tumor promoter-treated mouse epidermis and in primary mouse skin tumors induced by an initiation-promotion protocol. Mol Carcinog 1998; 22: 73-83.
7. DiGiovanni J, Kiguchi K, Frijhoff A et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000; 97: 3455-60.
8. Ali IU. Gatekeeper for endometrium: the PTEN tumor suppressor gene. J Natl Cancer Inst 2000; 92: 861-3.
9. Suzuki A, de la Pompa JL, Stambolic V et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-78.
10. Suzuki A, Itami S, Ohishi M et al. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 2003; 63: 674-81.
11. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003; 115: 145-67.
12. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002; 27: 462-7.
13. Stambolic V, MacPherson D, Sas D et al. Regulation of PTEN transcription by p53. Mol Cell 2001; 8: 317-25.
14. Freeman DJ, Li AG, Wei G et al. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003; 3: 117-30.
15. Suzuki A, Yamaguchi MT, Ohteki T et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523-34.
16. Tarutani M, Itami S, Okabe M et al. Tissue-specific knockout of the mouse Pig-a gene reveals important roles for GPI-anchored proteins in skin development. Proc Natl Acad Sci USA 1997; 94: 7400-5.
17. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992; 54: 63-128.
18. Umeda J, Sano S, Kogawa K et al. In vivo cooperation between Bcl-xL and the phosphoinositide 3-kinase-Akt signaling pathway for the protection of epidermal keratinocytes from apoptosis. FASEB J 2003; 17: 610-20.
19. Rodriguez-Villanueva J, Greenhalgh D, Wang, XJ et al. Human keratin-1.bcl-2 transgenic mice aberrantly express keratin 6, exhibit reduced sensitivity to keratinocyte cell death induction, and are susceptible to skin tumor formation. Oncogene 1998; 16: 853-63.
20. Manoharan K, Kinder D, Banerjee MR. DMBA induced DNA damage and repair in mammary epithelial cells in vitro measured by a nick translation assay. Cancer Biochem Biophys 1987; 9: 127-32.
21. Ise K, Nakamura K, Nakao K et al. Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. Oncogene 2000; 19: 2951-6.
22. Khosravi R, Maya R, Gottilieb T et al. Rapid ATM-dependent phospholylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci USA 1999; 96: 14973-7.
23. Yamasaki L. Role of the Rb tumor suppressor in cancer. Cancer Treat Res 2003; 115: 209-39.
24. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002; 27: 462-7.
25. Chene P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 2003; 3: 102-9.